ES2170161T3 - Nuevos conjugados de principios activos y proteinas. - Google Patents

Nuevos conjugados de principios activos y proteinas.

Info

Publication number
ES2170161T3
ES2170161T3 ES95932618T ES95932618T ES2170161T3 ES 2170161 T3 ES2170161 T3 ES 2170161T3 ES 95932618 T ES95932618 T ES 95932618T ES 95932618 T ES95932618 T ES 95932618T ES 2170161 T3 ES2170161 T3 ES 2170161T3
Authority
ES
Spain
Prior art keywords
protein
active
principles
new conjugates
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95932618T
Other languages
English (en)
Inventor
Hansjorg Sinn
Hans-Hermann Schrenk
Wolfgang Maier-Borst
Gerd Stehle
Andreas Wunder
Dirk Hoff-Biederbeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of ES2170161T3 publication Critical patent/ES2170161T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCION TRATA DE UN CONJUGADO FORMADO POR UN PRINCIPIO ACTIVO Y UNA PROTEINA NATIVA NO EXOGENA, QUE SE CARACTERIZA PORQUE ENTRE EL PRINCIPIO ACTIVO Y LA PROTEINA HAY UN LIGANTE QUE SE PUEDE DEGRADAR EN UNA CELULA. LA INVENCION TRATA TAMBIEN DE UN PROCEDIMIENTO PARA LA OBTENCION DE ESTA CONJUGADO Y LA UTILIZACION DEL MISMO.
ES95932618T 1994-09-22 1995-09-22 Nuevos conjugados de principios activos y proteinas. Expired - Lifetime ES2170161T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4433890A DE4433890C2 (de) 1994-09-22 1994-09-22 Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein

Publications (1)

Publication Number Publication Date
ES2170161T3 true ES2170161T3 (es) 2002-08-01

Family

ID=6528929

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95932618T Expired - Lifetime ES2170161T3 (es) 1994-09-22 1995-09-22 Nuevos conjugados de principios activos y proteinas.

Country Status (8)

Country Link
US (2) US6812209B1 (es)
EP (1) EP0782456B1 (es)
JP (1) JPH10505842A (es)
AT (1) ATE210465T1 (es)
DE (2) DE4433890C2 (es)
DK (1) DK0782456T3 (es)
ES (1) ES2170161T3 (es)
WO (1) WO1996009071A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59709788D1 (de) * 1997-05-09 2003-05-15 Deutsches Krebsforsch Konjugat, umfassend einen Folsäureantagonisten und einen Träger
EP1343531A2 (en) * 2000-12-21 2003-09-17 McGILL UNIVERSITY Conjugates of antibodies and anticancer drugs
US20020137901A1 (en) * 2001-01-22 2002-09-26 Cavanaugh Philip Gerard Synthesis, and photodynamic therapy-mediated anti-cancer, and other uses of chlorin e6-transferrin
US9458515B2 (en) 2010-03-11 2016-10-04 Riken RNA including nucleoside compound, method for regulating amount of protein produced from the RNA, and nucleoside compound

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3976763A (en) * 1975-04-30 1976-08-24 Hoffmann-La Roche Inc. Chlorpromazine assay
BE882541A (fr) * 1980-03-31 1980-07-16 Inst Internat De Pathologie Ce Nouvelles formes pharmaceutiques leur preparation et les compositions qui les contiennent
US5156840A (en) * 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
JPS59116229A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4456691A (en) 1983-02-28 1984-06-26 Suad Stark Antigen for PCB, antibody raised by same, and method of making same
US4522750A (en) * 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
US4731439A (en) * 1985-11-22 1988-03-15 Oncogen Snake venom growth arresting peptide
ES2001710A6 (es) * 1986-04-08 1988-06-01 Omnichem Sa Procedimiento de preparar conjugados de vinblastina y sus derivados
IN165717B (es) * 1986-08-07 1989-12-23 Battelle Memorial Institute
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5094848A (en) * 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
US5208323A (en) * 1989-08-10 1993-05-04 Universite Laval Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
US5140013A (en) * 1989-11-28 1992-08-18 Universite Laval Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
FI101678B1 (fi) * 1990-12-31 1998-08-14 Akzo Nv Happolabiileja kytkentämolekyylejä
DE4122210C2 (de) * 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers

Also Published As

Publication number Publication date
DK0782456T3 (da) 2002-04-08
US6812209B1 (en) 2004-11-02
EP0782456B1 (de) 2001-12-12
WO1996009071A1 (de) 1996-03-28
JPH10505842A (ja) 1998-06-09
DE4433890C2 (de) 1999-02-18
EP0782456A1 (de) 1997-07-09
US20010012885A1 (en) 2001-08-09
DE59509948D1 (de) 2002-01-24
DE4433890A1 (de) 1996-03-28
ATE210465T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
ES2099211T3 (es) Conjugados citomoduladores de miembros de parejas de union especifica.
UY24572A1 (es) Conjugados peg - interferon alfa
ES2115927T3 (es) Compuestos utilizados como blancos.
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
PE3796A1 (es) Un articulo absorbente
CL2003002786A1 (es) Composicion liofilizada que comprende i) una epotilona y ii) manitol o una ciclodextrina y composicion liofilizada que los comprende reconstituida con solvente, util como citotoxico en el tratamiento de tumores.
BR0213245A (pt) Dispositivo e sonda para a aplicação ocular de um princìpio ativo
NL185390B (nl) Element, bestemd voor implantatie in beenderweefsel.
ES2173284T3 (es) Agentes endoparasicitidas.
SV2002000315A (es) Combinaciones de productos activos con propiedades insecticidas y acaricidas ref. lea 34226-sv
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
ATE308999T1 (de) Intrazellulare expression von carboxypeptidase g2 in enzyme-prodrug-therapie
DOP2001000219A (es) Applicator
CO5001019A1 (es) Composicion emulsionable para la represion de insectos, que se deriva del tipo de fenilpirazoles sustituidos en posi- cion 1, y no favorecen la formacion de cristales
ES2046852T3 (es) Un procedimiento para preparar un champu.
ES2125873T3 (es) Plasmido hibrido para el antigeno con 38 kda de m. tuberculosis, e. coli como hospedante, el antigeno con 38 kda y una proteina con aproximadamente 33kda.
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
NO913035D0 (no) (2r)-2-(di(2-propyl)fosfonylmetoksy)-3-p-toluensulfonyloksy-1-trimetylacetoksypropan, fremgangsmaate for fremstilling og anvendelse derav.
BR0314787A (pt) Forma de dosagem de liberação modificada
WO2003045429A3 (en) Anti-t cell immunotoxin fusion protein and its therapeutic use
ES2040269T3 (es) Procedimiento para la obtencion de una inmunotoxina.
ES2156215T3 (es) Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias.
ES2175135T3 (es) Uso de galactanasa en piensos animales.
BR0111692A (pt) Processo para preparação de polipeptìdeo il-18 fisiologicamente ativo

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 782456

Country of ref document: ES